Xiang-Ru Shannon Xu

Xiang-Ru Shannon Xu

Auto-generated profile, based on publicly available information

Xiang-Ru Shannon Xu

Verily Life Sciences LLC., South San Francisco, California 94080, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAnnabel Guichard
Annabel Guichard
THTisha Haque
Tisha Haque
MBMarketta Bobik
Marketta Bobik
XXXiang-Ru S. Xu
Xiang-Ru S. Xu
CKCarissa Klanseck
Carissa Klanseck
EBEthan Bier
Ethan Bier
Gene-drive systems developed in several organisms result in super-Mendelian inheritance of transgenic insertions. Here, we generalize this “active genetic” approach to preferentially transmit allelic variants (allelic-drive) resulting from only a single or a few nucleotide alterations. We test two configurations for allelic-drive: one, copy-cutting, in which a non-preferred allele is selectively targeted for Cas9/guide RNA (gRNA) cleavage, and a more general approach, copy-grafting, that permits selective inheritance of a desired allele located in close proximity to the gRNA cut site. We also characterize a phenomenon we refer to as lethal-mosaicism that dominantly eliminates NHEJ-induced mutations and favors inheritance of functional cleavage-resistant alleles. These two efficient allelic-drive methods, enhanced by lethal mosaicism and a trans-generational drive process we refer to as “shadow-drive”, have broad practical applications in improving health and agriculture and greatly extend the active genetics toolbox.

20 May 2024 in Environmental Science & Technology Letters
Verified
Journal Article
Open access
MWMarlene K Wolfe
Marlene K Wolfe
DDDorothea Duong
Dorothea Duong
BSBridgette Shelden
Bridgette Shelden
ECElana M. G. Chan
Elana M. G. Chan
VCVikram Chan-Herur
Vikram Chan-Herur
ABAlexandria B. Boehm
Alexandria B. Boehm

8 January 2020 in Nature
Verified
Journal Article
Open access
PDF file
HGHannah A. Grunwald
Hannah A. Grunwald
VGValentino M. Gantz
Valentino M. Gantz
GPGunnar Poplawski
Gunnar Poplawski
XXXiang-Ru S. Xu
Xiang-Ru S. Xu
EBEthan Bier
Ethan Bier
KCKimberly L. Cooper
Kimberly L. Cooper
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.

23 December 2017 in eLife
Verified
Journal Article
Open access
XXXiang-Ru Shannon Xu
Xiang-Ru Shannon Xu
VGValentino Matteo Gantz
Valentino Matteo Gantz
NSNatalia Siomava
Natalia Siomava
EBEthan Bier
Ethan Bier
The knirps (kni) locus encodes transcription factors required for induction of the L2 wing vein in Drosophila. Here, we employ diverse CRISPR/Cas9 genome editing tools to generate a series of targeted lesions within the endogenous cis-regulatory module (CRM) required for kni expression in the L2 vein primordium. Phenotypic analysis of these ‘in locus’ mutations based on both expression of Kni protein and adult wing phenotypes, reveals novel unexpected features of L2-CRM function including evidence for a chromosome pairing-dependent process that promotes transcription. We also demonstrate that self-propagating active genetic elements (CopyCat elements) can efficiently delete and replace the L2-CRM with orthologous sequences from other divergent fly species. Wing vein phenotypes resulting from these trans-species enhancer replacements parallel features of the respective donor fly species. This highly sensitive phenotypic readout of enhancer function in a native genomic context reveals novel features of CRM function undetected by traditional reporter gene analysis.

25 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CCChristopher M. Conner
Christopher M. Conner
DFDon van Fossan
Don van Fossan
KRKristen Read
Kristen Read
DCDale Cowley
Dale Cowley
OAOscar Alvarez
Oscar Alvarez
KJKurt Jarnagin
Kurt Jarnagin
Monoclonal antibodies (mAbs) are one of the fastest-growing classes of drugs and have been approved to treat several diseases, including cancers and autoimmune disorders. Preclinical pharmacokinetics studies are performed to determine the therapeutically meaningful dosages and efficacy of candidate drugs. These studies are typically performed in non-human primates; however, using primates is costly and raises ethical considerations. As a result, rodent models that better mimic human-like pharmacokinetics have been generated and remain an area of active investigation.Pharmacokinetic characteristics of a candidate drug, such as half-life, are partly controlled by antibody binding to the human neonatal receptor hFCRN. Due to the abnormally high binding of human antibodies to mouse FCRN, traditional laboratory rodents do not accurately model the pharmacokinetics of human mAbs. In response, humanized rodents expressing hFCRNhave been generated. However, these models generally use large inserts randomly integrated into the mouse genome. Here, we report the production and characterization of a CRISPR/Cas9-mediated hFCRNtransgenic mouse termed SYNB-hFCRN. Using CRISPR/Cas9-assisted gene targeting, we prepared a strain with a simultaneous knockout of mFcrnand insertion of a hFCRNmini-gene under the control of the endogenous mouse promoter. These mice are healthy and express hFCRN in the appropriate tissues and immune cell subtypes. Pharmacokinetic evaluation of human IgG and adalimumab (Humira®) demonstrate hFCRN-mediated protection. These newly generated SYNB-hFCRNmice provide another valuable animal model for use in preclinical pharmacokinetics studies during early drug development.Materials availability: Cryopreserved germline cells from the strains are available from the MMRRC. Dr. Jarnagin will provide sequencing and other evidence supporting strain identity and the plasmids used for constructions.